Description

Copegus Indications

Hypersensitivity to ribavirin and other components of the drug;

– pregnancy (Copegus® drug treatment can be initiated only after a negative pregnancy test immediately prior to treatment) and during lactation; severe cardiac pathology in history, including unstable and uncontrolled cardiac pathology within the previous 6 months; severe liver dysfunction or uncompensated cirrhosis;

– hemoglobinopathies (thalassemia, anemia serpopodibnoklitynna);

– treatment of peginterferon alfa-2a is contraindicated in patients with co-infection of HIV-HCV with cirrhosis on a scale Child-Pugh ≥ 6, provided that the increase in this indicator is not associated with indirect hyperbilirubinemia as a result of taking the drugs, such as atazanavir and indinavirC

In addition to the combined treatment of peginterferon alfa-2a or interferon alfa-2a plus ribavirin.

It should be considered contraindications for the use of peginterferon alfa-2a or interferon alfa-2a.

Dosage & Administration

Therapy should carry a doctor who has experience in the treatment of chronic hepatitis C. Copegus® should be taken twice daily (morning and evening) during food intake. Due to the teratogenic potential of ribavirin tablets should not crush or grind.

Copegus® be used in combination with peginterferon alfa-2a or interferon alfa-2a. The exact dose and duration depends on the drug interferon used.